ArticleNanoscale research letters2018
Antiproliferative and Apoptosis Triggering Potential of Paclitaxel-Based Targeted-Lipid Nanoparticles with Enhanced Cellular Internalization by Transferrin Receptors-a Study in Leukemia Cells.
Article in Nanoscale research letters, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Advances in ligand-targeted nanodelivery systems for leukemia therapy: from single- to dual-ligand strategies.Journal of translational medicine · 2026Review
- Drug Release, Entrapment Efficacy, and Drug Loading Capacity of Taxanes Loaded Solid Lipid Nanoparticles (SLNs).Anti-cancer agents in medicinal chemistry · 2026Review
- Ibrutinib Loaded Nanostructured Lipid Carriers for the Management of Chronic Lymphocytic Leukemia: SynchronizingCurrent pharmaceutical design · 2026Article
- Nanocarrier-based immunotherapy for viral diseases.International journal of pharmaceutics: X · 2025Review
- Nanotechnology in leukemia: diagnosis, efficient-targeted drug delivery, and clinical trials.European journal of medical research · 2023Review
- Retraction Note: The BET inhibitor I-BET762 inhibits pancreatic ductal adenocarcinoma cell proliferation and enhances the therapeutic effect of gemcitabine.Scientific reports · 2023Article
- Lipid polymer hybrid nanoparticles: a custom-tailored next-generation approach for cancer therapeutics.Molecular cancer · 2023Review
- Solid Lipid Nanoparticles vs. Nanostructured Lipid Carriers: A Comparative Review.Pharmaceutics · 2023Review
- New trends in diagnosing and treating ovarian cancer using nanotechnology.Frontiers in bioengineering and biotechnology · 2023Review
- Article
- DNA damage and antioxidant properties of CORM-2 in normal and cancer cells.Scientific reports · 2020Article
- Transferrin Receptor Targeted Cellular Delivery of Doxorubicin Via a Reduction-Responsive Peptide-Drug Conjugate.Pharmaceutical research · 2019Article
- Nanoparticles for hematologic diseases detection and treatment.Hematology & medical oncology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Leukemia is a typical blood cancer that is characterized by the numerous duplication and proliferation of white blood cells. The main aim of this study was to develop PTX-loaded multifunctional nanoparticles and target to leukemia cells. In this study, transferrin-decorated paclitaxel-loaded lipid nanoparticle (TPLN) was prepared with an aim to increase the chemotherapeutic efficacy in the leukemia cells. Results clearly showed the superior targeting potential of TPLN to the HL-60 cancer cells compared to that of the paclitaxel-loaded nanoparticles (PLN). To be specific, TPLN showed a significantly higher cytotoxic effect in the cancer cells compared to that of the PLN indicating the superior targeting efficiency of the Tf-decorated nanoparticle system. The IC50 value of TPLN was 0.45 μg/ml compared to 2.8 μg/ml for PLN. TPLN induced a most remarkable apoptosis of the cancer cells and much of the cells were distorted with huge presence of the apoptotic body formation. Importantly, TPLN showed a remarkable reduction in the viable cells proportion to ~ 65% with around ~ 30% apoptosis cells (early and late apoptosis). Overall, results clearly showed the targeting potential of ligand-conjugated lipid nanoparticle system to the leukemia cells that might pave the way for the successful cancer treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.